ホーム › 膵臓がん › カリフォルニア州 › San Francisco
San Francisco、CAにおける膵臓がんの臨床試験
San Franciscoとその周辺地域（約30マイル以内）の拠点で、膵臓がんに関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- Kaiser Permanente-San Francisco, San Francisco
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第3相
- University of California, San Francisco, San Francisco
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
被験者募集中第3相
- Investigative Site US034, San Francisco
UCSF PANC Cyst Registry
被験者募集中観察研究
- University of California, San Francisco, San Francisco
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
被験者募集中観察研究
- University of California, San Francisco, San Francisco
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
被験者募集中第2相
- Local Institution - 0096, San Francisco
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
被験者募集中観察研究
- UCSF Medical Center-Mount Zion, San Francisco
- UCSF Medical Center-Parnassus, San Francisco
- UCSF Medical Center-Mission Bay, San Francisco
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
被験者募集中第3相
- California Pacific Medical Center-Pacific Campus, San Francisco
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
被験者募集中第1相
- UCSF, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- University of California San Francisco Cancer Center, San Francisco
Pancreatic Cancer Early Detection Consortium
被験者募集中観察研究健康なボランティア歓迎
- University of California, San Francisco (UCSF), San Francisco
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
被験者募集中第3相
- California Pacific Medical Center-Pacific Campus, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
被験者募集中
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
A Study of MGC028 in Participants With Advanced Solid Tumors
被験者募集中第1相
- UCSF - Helen Diller Family Cancer Center, San Francisco
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
被験者募集中早期第1相
- Stanford University, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
被験者募集中第1/2相
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
被験者募集中第2相
- Ohio State University-Telemedicine, San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
被験者募集中第1/2相
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, San Francisco
他の都市における膵臓がんの試験
- Houston, TX61件の研究
- New York City, NY60件の研究
- Boston, MA43件の研究
- Nashville, TN39件の研究
- Los Angeles, CA35件の研究
- St. Louis, MO33件の研究
- Arlington, VA33件の研究
- Baltimore, MD31件の研究
- San Antonio, TX31件の研究
- Philadelphia, PA26件の研究
- Tampa, FL26件の研究
- Durham, NC24件の研究
San Franciscoにおける他の研究
- 前立腺がん45件の研究
- 乳がん43件の研究
- 非小細胞肺癌36件の研究
- がん（全種類）35件の研究
- 心不全29件の研究
- 転移性癌28件の研究
- 肺がん22件の研究
- 悪性黒色腫22件の研究
- 卵巣がん19件の研究
- 大腸癌18件の研究
- 心血管疾患18件の研究
- 膠芽腫17件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。